MidFirst Bank Invests $1.10 Million in Gilead Sciences, Inc. $GILD

MidFirst Bank purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,967 shares of the biopharmaceutical company’s stock, valued at approximately $1,101,000.

Several other institutional investors also recently bought and sold shares of GILD. Paulson Wealth Management Inc. increased its stake in Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares in the last quarter. Essex Financial Services Inc. boosted its stake in shares of Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares during the last quarter. Alpha Cubed Investments LLC boosted its stake in shares of Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after acquiring an additional 75 shares during the last quarter. Personal CFO Solutions LLC raised its stake in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its stake in Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have issued reports on GILD. Barclays assumed coverage on shares of Gilead Sciences in a research note on Friday, February 20th. They set an “equal weight” rating and a $155.00 target price on the stock. Morgan Stanley decreased their price target on shares of Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Jefferies Financial Group started coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective for the company. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Finally, Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a report on Wednesday, May 20th. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $158.41.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares in the company, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock valued at $8,930,150 in the last quarter. Insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $123.76 on Friday. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The company has a 50-day moving average price of $131.66 and a 200 day moving average price of $134.21. Gilead Sciences, Inc. has a 12-month low of $104.46 and a 12-month high of $157.29. The stock has a market cap of $153.66 billion, a P/E ratio of 16.86 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the previous year, the company earned $1.81 EPS. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s payout ratio is currently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.